Example searches

GSK GlaxoSmithKline plc

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Company profile

Ticker
GSK, GLAXF
Exchange
NYSE
Website
gsk.com
CEO
Emma N. Walmsley
Employees
Incorporated
United Kingdom
Location
United Kingdom
Sector
Health Technology > Pharmaceuticals: Major
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Teva Pharmaceutical Industries Limited • Bristol-Myers Squibb • Eli Lilly and • Warner Chilcott • AbbVie ...
SEC CIK
0001131399
Corporate docs

GSK stock data

(
)

Calendar

6 Mar 20
24 Nov 20

News

Recent insider trades

GSK insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
24 Jul 20 GlaxoSmithKline Common Stock Buy Aquire P No 2.25 1,260,504 2.84M 4,626,389
24 Jul 20 GlaxoSmithKline Warrant Common Stock Buy Aquire P No 0.125 1,260,504 157.56K 1,260,504
21 Jul 20 GlaxoSmithKline Common Stock Buy Aquire P No 18 361,111 6.5M 2,248,304
21 Jul 20 GlaxoSmithKline Common Stock Conversion Aquire C No 0 348,469 0 1,887,193
21 Jul 20 GlaxoSmithKline Common Stock Conversion Aquire C No 0 1,538,724 0 1,538,724
21 Jul 20 GlaxoSmithKline Series B Preferred Stock Common Stock Conversion Dispose C No 0 1,776,980 0 0
21 Jul 20 GlaxoSmithKline Series A Preferred Stock Common Stock Conversion Dispose C No 0 7,846,554 0 0
17 Jul 20 GlaxoSmithKline Stock Option Common Stock Grant Aquire A No 18 13,997 251.95K 13,997
15 Jul 20 GlaxoSmithKline Common Stock Sell Dispose S No 19.25 78 1.5K 1,910,531
15 Jul 20 GlaxoSmithKline Common Stock Sell Dispose S No 19.4016 3,069 59.54K 1,910,609
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q3 2020

GSK institutional ownership history Ownership history
11.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 784 808 -3.0%
Opened positions 72 88 -18.2%
Closed positions 96 71 +35.2%
Increased positions 230 258 -10.9%
Reduced positions 321 311 +3.2%
13F shares
 Current Prev Q Change
Total value 11.13B 12.39B -10.2%
Total shares 295.99M 304.02M -2.6%
Total puts 1.79M 1.96M -8.4%
Total calls 1.95M 2.06M -5.3%
Total put/call ratio 0.9 1.0 -3.2%
Largest owners
 Shares Value Change
Dodge & Cox 45M $1.69B +8.4%
FMR 19.76M $743.89M -1.0%
Renaissance Technologies 18.33M $689.93M -10.8%
N Price T Rowe Associates 17.69M $665.79M +0.4%
Capital International Investors 16.51M $621.19M -12.3%
Fisher Asset Management 16.23M $610.76M +2.2%
RY Royal Bank of Canada 15.56M $585.85M -7.2%
STT State Street 9.39M $357.91M +0.8%
Hotchkis & Wiley Capital Management 7.4M $278.71M +2.5%
Black Creek Investment Management 6.49M $244.13M +11.9%
Largest transactions
 Shares Bought/sold Change
Dodge & Cox 45M +3.48M +8.4%
Camber Capital Management 450K -2.55M -85.0%
Capital International Investors 16.51M -2.32M -12.3%
Renaissance Technologies 18.33M -2.22M -10.8%
Two Sigma Investments 170.32K -1.38M -89.0%
Jane Street 1.39M +1.21M +673.7%
RY Royal Bank of Canada 15.56M -1.2M -7.2%
Ubs Global Asset Management Americas 83.3K -1.12M -93.1%
Connor, Clark & Lunn Investment Management 0 -808.17K EXIT
American Century Companies 2.84M +698.05K +32.5%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Chattem • Imclone Systems • Aventis • Sicor • Orchestra Therapeutics • Heron Therapeutics • ImmunoCellular Therapeutics • GeoVax Labs • Delcath Systems • Icos
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abnormal, accrual, actuarial, Additionally, adequacy, administering, agent, aim, alfa, alter, analyst, analytical, andAdvil, andBenlysta, andDovato, andMaxinutrition, area, arena, arisen, Artificial, assumption, avenue, belantamab, biggest, billing, bintrafusp, biography, biosimilar, branch, bribe, briefly, budgeting, bullet, buy, buying, buyout, byAugmentin, byTivicay, cap, CCL, chargeback, Chase, clawback, closer, closest, closure, column, Commodity, compel, complementary, compound, contradictory, corroborative, Council, country, coupled, CROIC, cumulative, Custodian, cyberattack, deficit, depreciation, describedin, difficulty, discontinued, dispute, dissemination, dostarlimab, easier, element, eliminating, EMA, embed, embedded, entirety, ESOP, EURIBOR, evasion, exact, ExcludingAdvair, explicitly, externalised, false, FCA, floating, formulary, forward, fragmented, frequency, GBP, genericAdvair, genericisation, globe, great, greatest, handling, harder, hazard, Hindustan, honoured, IASB, IFRIC, immune, Immunopharma, inBoostrix, includingLamictal, indemnification, Index, inFlonase, inJuluca, injury, instability, Intelligence, interrogation, inTheraflu, inTriumeq, invoice, invoiced, invoicing, IPO, IPTc, irrevocably, Jonathan, JPMorgan, judgement, KgaA, laboratory, lag, laundering, leader, LIBOR, longest, lowerCervarix, Lyell, Lynch, macro, mainland, match, matched, matching, Medicaid, Medicare, Merck, Merrill, methodology, monthly, Moody, Morgan, move, moving, negotiate, novation, ofChapStick, ofDovato, offence, ofPanadol, ofShingrix, ofTrelegy, ofTrelegyEllipta, ofViread, ofZejula, onAdvair, online, onTrelegy, optimise, OT, output, Overnight, pace, particularlyShingrix, passage, past, pattern, persuade, PF, picture, prescription, President, primarilyZejula, prioritise, privileged, program, Progyny, ratio, rationalisation, ready, Recalculated, Redburn, refinanced, reinforcing, reinvested, remote, repayable, reprioritisation, repurchased, retrospective, reversal, rheumatoid, sample, scale, serialisation, short, shortly, simply, situation, smooth, Society, SOFR, SONIA, speculative, speedy, standalone, Stanley, store, STR, substantive, successor, Suisse, suit, swap, swapped, SWIFT, TCO, theft, TMG, toBexsero, trail, ultimate, unavailability, unconditional, underway, undue, Unilever, unintended, uninterrupted, uplift, usage, USD, vendor, verified, Vice, vulnerable, welfare, window, withTriumeq, yearAdvair
Removed: accrue, adapt, administration, anaemia, andRotarix, andSensodyne, annum, API, Aspen, attempt, attributable, bearing, Bright, broader, capitalised, cGMP, consistency, controlled, corrupted, decreased, demonetisation, East, embodiment, EU, GMP, immunisation, Japan, John, label, mid, Middle, mission, momentum, Nigeria, obligated, overarching, Patrick, preclinical, predominantly, proactively, protecting, remedial, remediation, restriction, SE, Setfirst, Simon, sound, substitutable, supplier, surrendering, TheAvodart, thereon, Thompson, true, unwinding, Vallance, variant, whileAugmentin, winding
From filing 20-F 2019 FY

Financial reports

View all
20-F
2019 FY
Annual report (foreign)
6 Mar 20
20-F
2018 FY
Annual report (foreign)
15 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
20 Mar 18
20-F
2017 FY
Annual report (foreign)
16 Mar 18
20-F
2016 FY
Annual report (foreign)
17 Mar 17
20-F
2015 FY
Annual report (foreign)
18 Mar 16
20-F
2014 FY
Annual report (foreign)
27 Feb 15
20-F
2013 FY
Annual report (foreign)
28 Feb 14
20-F
2012 FY
Annual report (foreign)
8 Mar 13
20-F
2011 FY
Annual report (foreign)
13 Mar 12

Current reports

View all
6-K
Block Listing Interim Review
23 Nov 20
6-K
Holding(s) In Company
19 Nov 20
6-K
Director/pdmr Shareholding
17 Nov 20
6-K
Medicago GSK Phase 2/3 Study Start
12 Nov 20
6-K
Director/pdmr Shareholding
12 Nov 20
6-K
Director/pdmr Shareholding
12 Nov 20
6-K
Viiv's Cabotegravir Superior for Hiv Prevention
9 Nov 20
6-K
Director/pdmr Shareholding
4 Nov 20
6-K
Director/pdmr Shareholding
4 Nov 20
6-K
Director/pdmr Shareholding
3 Nov 20

Registration and prospectus

View all
25-NSE
Exchange delisting
13 Oct 20
8-A12B
Registration of securities on exchange
1 Oct 20
424B2
Prospectus for primary offering
30 Sep 20
FWP
Free writing prospectus
28 Sep 20
FWP
Free writing prospectus
28 Sep 20
424B2
Prospectus for primary offering
28 Sep 20
S-8
Registration of securities for employees
20 Dec 19
F-6
Registration for ADRs (foreign)
19 Jul 19
8-A12B
Registration of securities on exchange
25 Mar 19
424B2
Prospectus for primary offering
20 Mar 19

Proxies

No filings

Other

View all
SD
Conflict minerals disclosure
29 May 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 20
EFFECT
Notice of effectiveness
30 Jul 19
SD
Conflict minerals disclosure
31 May 19
CT ORDER
Confidential treatment order
2 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Mar 19
SD
Conflict minerals disclosure
30 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
16 Mar 18
SD
Conflict minerals disclosure
31 May 17
EFFECT
Notice of effectiveness
18 Apr 17

Ownership

View all
SC 13D/A
Turning Point Therapeutics / GLAXOSMITHKLINE ownership change
6 Nov 20
SC 13D/A
Principia Biopharma / GLAXOSMITHKLINE ownership change
1 Oct 20
4
Change in insider ownership
18 Sep 20
SC 13G
CureVac / GLAXOSMITHKLINE ownership change
24 Aug 20
SC 13D
Pandion Therapeutics / GLAXOSMITHKLINE ownership change
3 Aug 20
4
Change in insider ownership
31 Jul 20
SC 13D
Nkarta / GLAXOSMITHKLINE ownership change
22 Jul 20
4
Change in insider ownership
22 Jul 20
3
Initial statement of insider ownership
17 Jul 20
4
Change in insider ownership
17 Jul 20